Yu Kasamatsu

Dr. Yu Kasamatsu


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2022 in Medicine
Verified
Journal Article
Open access
KKKeiji Konishi
Keiji Konishi
HNHidenori Nakagawa
Hidenori Nakagawa
TATomohiro Asaoka
Tomohiro Asaoka
YKYu Kasamatsu
Yu Kasamatsu
TGTetsushi Goto
Tetsushi Goto
MSMichinori Shirano
Michinori Shirano
To investigate the prevalence of sarcopenia among people living with HIV (PLWH) in Japan and analyze the relationship between HIV infection and ART effects on the body composition of Japanese PLWH for more appropriate drug selection and lifestyle guidance. Cross-sectional observational study. We included male patients aged ≥ 60 years whose body composition was measured by InBody 570 body composition analyzer during outpatient visits. Patients were classified by body shape based on body mass index (BMI) and body fat percentage measurements and by tenofovir alafenamide administration. Hidden obesity is a condition wherein the BMI is within the standard range but the body fat percentage is higher than the reference. Patients with low muscle mass and strength were considered to have sarcopenia, whereas those with only low muscle strength were considered to have pre-sarcopenia. In total, 87 patients were included. Based on body shape determined by BMI and body fat percentage, most patients had hidden obesity (40 patients, 46.0%). Sarcopenia was detected in 9 patients (10.3%) and pre-sarcopenia in 14 patients (16.1%). The tenofovir alafenamide (TAF) use group had significantly higher BMI, higher skeletal muscle mass, body fat mass, and skeletal muscle mass index relative to the non-TAF use group. Hidden obesity is a risk for lifestyle diseases. It is important to recognize it based on body composition measurements because it can be missed by BMI measurement alone. Tenofovir alafenamide therapy increases skeletal muscle mass, which may result in the prevention of sarcopenia. To clarify how TAF affects the development of sarcopenia and lifestyle diseases, future studies on a larger cohort are warranted.

13 May 2013 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
YKYu Kasamatsu
Yu Kasamatsu
TKTakashi Kida
Takashi Kida
MSMayumi Shigeru
Mayumi Shigeru
TTToru Tagashira
Toru Tagashira
NMNaoki Murai
Naoki Murai
HTHideyuki Takaoka
Hideyuki Takaoka
The clinical presentation of eosinophilic myocarditis may vary from asymptomatic to the manifestation of severe symptoms, including cardiac tamponade and arrhythmias. In pregnant patients with this condition, drugs must be used cautiously up to approximately the 4th month of pregnancy because drug use should be limited during the period of fetal organogenesis.

18 January 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
KSKumiko Shoji
Kumiko Shoji
MSMichinori Shirano
Michinori Shirano
MKMitsuru Konishi
Mitsuru Konishi
YTYuko Toyoshima
Yuko Toyoshima
MMMiyuki Matsumoto
Miyuki Matsumoto
DHDaiki Habu
Daiki Habu
Maintenance of the cluster of differentiation 4 (CD4) positive lymphocyte count (CD4 count) is important for human immunodeficiency virus (HIV) positive individuals. Although a higher body mass index (BMI) is shown to be associated with a higher CD4 count, BMI itself does not reflect body composition. Therefore, we examined the association of body weight, body composition and the CD4 count, and determined the optimal ranges of CD4 count associated factors in Japanese HIV positive individuals. This cross-sectional study included 338 male patients treated with antiretroviral therapy for ≥12 months. Multiple logistic regression analysis was used to identify factors significantly associated with a CD4 count of ≥500 cells (mm3)−1. The cutoff values of factors for a CD4 ≥ 500 cells (mm3)−1 and cardiovascular disease risk were obtained by receiver operating characteristic curves. Age, body fat percentage (BF%), nadir CD4 count, duration of antiretroviral therapy (ART), years since the HIV-positive diagnosis and cholesterol intake showed significant associations with the CD4 count. The cutoff value of BF% for a CD4 ≥ 500 cells (mm3)−1 and lower cardiovascular disease risk were ≥25.1% and ≤25.5%, respectively. The BF%, but not the BMI, was associated with CD4 count. For the management of HIV positive individuals, 25% appears to be the optimal BF% when considering the balance between CD4 count management and cardiovascular disease risk.

23 April 2026 in Cureus
Verified
Journal Article
Open access
PDF file
YKYu Kasamatsu
Yu Kasamatsu
SSSatoshi Shiraisi
Satoshi Shiraisi
MUMasato Uji
Masato Uji
MKMasanori Kobayashi
Masanori Kobayashi
TGTetsushi Goto
Tetsushi Goto
YHYoshikazu Hiura
Yoshikazu Hiura
Ensitrelvir inhibits the 3-chymotrypsin-like protease of severe acute respiratory syndrome coronavirus 2 and accelerates viral clearance and symptom improvement through its potent antiviral activity. Reports of rebound after ensitrelvir treatment are scarce. This report presents a case of a healthcare worker in her 50s who had no significant underlying conditions. As a close contact, she underwent nasopharyngeal polymerase chain reaction (PCR) testing after her sister was diagnosed with coronavirus disease. The test result was positive with a cycle threshold (Ct) value of 31.97 by using Cobas® liat. Ensitrelvir treatment was initiated because of a slight sore throat, and rapid improvement was observed starting the following day. Treatment was completed on day five. Examination on day six indicated that the symptoms had resolved. However, the sore throat recurred on day seven, antigen levels increased again, and fever and cough developed on day eight. On day nine, a Ct value of 16.6 was noted, suggesting a strongly positive result and rebound. She received five vaccine doses and had markedly high levels of anti-S immunoglobulin G (IgG) antibodies, but her anti-N IgG antibodies were negative, indicating that she had a normal immune response and had not been infected with COVID-19. Her illness was mild, and symptoms peaked on day 11, without additional treatment. This case strongly suggests viral rebound and symptom relapse after ensitrelvir administration. Therefore, caution is warranted, as rebound may occur after ensitrelvir treatment, similar to that after nirmatrelvir/ritonavir treatment.